Jonathan Tobin

Jonathan is a Partner with Brandon Capital where he heads the London office, and serves on the boards of Brandon portfolio companies Astronautx, Pheon Therapeutics, Myricx Bio, NRG Therapeutics, and Catalym. Prior to joining Brandon, Jonathan was a Managing Director at Arix Bioscience, a UK and US-based biotech venture firm, where he helped build the team and portfolio, and sat on the boards of a number of companies. Prior to Arix, he was a Principal of Imperial Innovations/Touchstone Innovations PLC and helped create and build several university spinouts.  

Jonathan has a degree in Biology from the University of Oxford; a PhD in Molecular Medicine from UCL focusing on rare genetic diseases; carried out postdoctoral research on cancer cell signalling at the Cancer Research UK London Research Institute (now The Francis Crick Institute), and an MBA with Distinction from Imperial College London. He serves as a trustee on the board of the Autism Centre for Excellence in Cambridge, and is a member of the Investment Advisory Committee of the KHAN drug discovery fund in Germany.